ReviewChinese journal of cancer research = Chung-kuo yen cheng yen chiu2016
The update of prostatic ductal adenocarcinoma.
Review in Chinese journal of cancer research = Chung-kuo yen cheng yen chiu, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- [Clinical characteristics and influencing factors of extraglandular invasion of prostatic ductal adenocarcinoma].Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2025Article
- Ductal Adenocarcinoma of the Prostate Presenting With Bladder Invasion and Bone Metastasis: A Case Report.Cureus · 2025Article
- The Prognostic Value of the Prostate Adenocarcinoma With Ductal Feature in Patients With Advanced Prostate Cancer Treated With Abiraterone Acetate.The Prostate · 2025Article
- Prostatic duct adenocarcinoma-A challenging variant of prostate cancer in a low-resource setting.Clinical case reports · 2024Article
- Ductal adenocarcinoma of the prostate or seminal vesicle adenocarcinoma: An multi-disciplinary team (MDT) case report and literature review.Current urology · 2022Article
- Optimizing the diagnosis and management of ductal prostate cancer.Nature reviews. Urology · 2021Review
- Ductal adenocarcinoma of the prostate: A systematic review and meta-analysis of incidence, presentation, prognosis, and management.BJUI compass · 2021Review
- Sox2 is necessary for androgen ablation-induced neuroendocrine differentiation from Pten null Sca-1Oncogene · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since initially described in 1967, prostatic ductal adenocarcinoma (PDA) has engendered a series of controversies on its origin, histological features, and biological behavior. Owing to the improvement of molecular biological technique, there are some updated findings on the characteristics of PDA. In the current review, we will mainly analyze its origin, clinical manifestations, morphological features, differential diagnosis, immunophenotype and molecular genetics, with the purpose of enhancing recognition of this tumor and making a correct diagnosis and treatment choice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.